Yazarlar : Schmitz MF, Otten HG, Franssen LE et al

Yayın : Haematologica.

Yayın Yılı : 2014

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/25193963

Konu : Myelom

Literatür İçeriği :  In the course of multiple myeloma, patients may develop a M-protein band different from the original: secondary monoclonal gammopathy of undetermined significance. In this retrospective single centre analysis we describe the occurrence and clinical relevance of secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation (post-transplant monoclonal gammopathy of undetermined significance). We included a total of 138 patients who underwent 139 allogeneic stem cell transplantations (39.6% in the upfront setting and 60.4% for relapsed multiple myeloma). Sixty-seven (48.2%) patients developed secondary monoclonal gammopathy of undetermined significance, after a median latency of 6.9 months. Secondary monoclonal gammopathy of undetermined significance occurred more often in patients who achieved at least very good partial response after allogeneic stem cell transplantation, compared to partial response or less (54.8% vs 26.5%, P=0.005). The incidence was also higher in the upfront setting as compared to relapsed disease, or with a sibling donor compared to matched unrelated donor, but less often after T cell depletion. Importantly, development of post-transplant monoclonal gammopathy of undetermined significance as a time-dependent variable, independently predicted for superior progression-free and overall survival (median progression-free survival: 37.5 vs 6.3 months, P<0.001; median overall survival: 115.3 vs 31.0 months, P=0.004). Clinicians should be aware of the benign nature of this phenomenon, and secondary monoclonal gammopathy of undetermined significance should not be confused with relapse or progression of disease. Trial is registered with trialregister.nl; HOVON 108: NTR 2958.

Literatür Arşivi